The next stage
Calcivis, a medical devices company focused on revolutionising the management of tooth decay and enabling preventive dentistry, has announced that it has been accepted into the next cohort of the London Stock Exchange (LSE)’s Elite programme that supports ambitious companies towards growth and investment.
Elite is a unique programme designed to support exciting and ambitious private companies prepare and structure for their next stage of growth. The programme facilitates structured engagement between Calcivis, entrepreneurs and business leaders, as well as the corporate advisory and investor community, through a package of education, business support and access to investors.
Adam Christie, CEO of Calcivis, said: “We are pleased that Calcivis has been accepted for the LSE’s Elite programme. This is a significant achievement and reflects the LSE’s appreciation of the potential of our unique technology that will, for the first time, allows dentists to visualise active demineralisation, a key step to them practising the preventive management of tooth decay. We are excited about this programme which will provide us with support as we embark on the next phase of our growth including launch of the Calcivis System in the UK market next year, together with a premarket authorisation filing to FDA in advance of marketing in the US.”
Register now to continue reading
WHAT’S INCLUDED
-
Unlimited access to the latest news, articles and video content
-
Monthly email newsletter
-
Podcasts and members benefits, coming soon!